Paeds Cases · infectious-diseases
Explaining an HIV-exposed infant's diagnosis and feeding plan — OSCE
Communication and structured-discussion OSCE on explaining the management of an HIV-exposed newborn to a mother newly diagnosed in pregnancy, covering why the baby's antibody test is not yet meaningful, the nevirapine prophylaxis and cotrimoxazole plan, the PCR testing schedule, the feeding decision, and how the mother's own viral suppression protects the baby.
On this page & tools
Target exams
Candidate instructions (8-minute station)
You are the paediatric registrar on the postnatal ward. A term, well infant has just been born to a 28-year-old mother who was diagnosed with HIV at 24 weeks of pregnancy and started on combination antiretroviral therapy; her viral load is now suppressed. [7]
Your tasks are: [7]
- Explain why the baby's HIV antibody test will be positive but does not mean the baby is infected, and how infection will actually be confirmed or excluded. [7]
- Explain the infant's medication — nevirapine prophylaxis and, from a few weeks, cotrimoxazole — and what each is for. [7] [8]
- Explain the HIV PCR testing schedule, including the final antibody test at 18 to 24 months. [7]
- Advise on infant feeding, and explain how the mother's own viral suppression is the most important protection for the baby. [3] [7]
You are not expected to adjust the mother's own HIV medications — her HIV physician retains that — but you should reinforce the importance of her staying on treatment and engaged in care. [7]
You have read the opening of this case. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References4Show ledgerHide ledger
- [1]Violari A; Cotton MF; Gibb DM; Babiker AG; et al Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med, 2008.PMID 19020325
- [3]Jamieson DJ; Chasela CS; Hudleston MG; King CC; et al Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet, 2012.PMID 22541418
- [7]Havens PL; Mofenson LM; American Academy of Pediatrics Committee on Pediatric AIDS Evaluation and management of the infant exposed to HIV-1 in the United States. Pediatrics, 2009.PMID 19117880
- [8]Mofenson LM; Brady MT; Danner SP; Dominguez KL; et al Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children. MMWR Recomm Rep, 2009.PMID 19730409